Loading news...
Inhibikase Therapeutics, Inc. (NASDAQ: IKT - Get Free Report) was the target of a significant increase in short interest in the month of February. As of February 27th, there was short interest totaling 16,041,114 shares, an increase of 52.2% from the February 12th total of 10,541,776 shares. Based on an average daily trading volume, of 3,478,233
Inhibikase Therapeutics (NYSE: IKT - Get Free Report) and Big Cypress Acquisition (OTCMKTS:BCYP - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends. Profitability This table compares Inhibikase Therapeutics
Inhibikase Therapeutics, Inc. (NASDAQ: IKT - Get Free Report) has been given a consensus recommendation of "Buy" by the five research firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a strong buy recommendation
Big Cypress Acquisition (OTCMKTS:BCYP - Get Free Report) and Inhibikase Therapeutics (NYSE: IKT - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, profitability and risk. Analyst Ratings This is a summary
Liminatus Pharma (NASDAQ: LIMN - Get Free Report) and Inhibikase Therapeutics (NASDAQ: IKT - Get Free Report) are both small-cap manufacturing companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, dividends and analyst recommendations. Valuation and Earnings This table compares Liminatus
Liminatus Pharma (NASDAQ: LIMN - Get Free Report) and Inhibikase Therapeutics (NASDAQ: IKT - Get Free Report) are both small-cap manufacturing companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, risk, institutional ownership and valuation. Analyst Recommendations This is a breakdown of
Inhibikase Therapeutics (NASDAQ: IKT - Get Free Report) and Liminatus Pharma (NASDAQ: LIMN - Get Free Report) are both small-cap manufacturing companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, valuation, analyst recommendations, dividends and institutional ownership. Profitability This table compares Inhibikase Therapeutics and
Liminatus Pharma (NASDAQ: LIMN - Get Free Report) and Inhibikase Therapeutics (NASDAQ: IKT - Get Free Report) are both small-cap manufacturing companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, earnings, dividends and risk. Profitability This table compares Liminatus Pharma and
Inhibikase Therapeutics (NASDAQ: IKT - Get Free Report) and Liminatus Pharma (NASDAQ: LIMN - Get Free Report) are both small-cap manufacturing companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, analyst recommendations and earnings. Valuation and Earnings This table compares Inhibikase
Liminatus Pharma (NASDAQ: LIMN - Get Free Report) and Inhibikase Therapeutics (NASDAQ: IKT - Get Free Report) are both small-cap manufacturing companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk. Analyst Recommendations This is a summary of
WILMINGTON, Del., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of pulmonary arterial hypertension (“PAH”), today announced the pricing of its underwritten public offering of 46,091,739 shares of common stock and pre-funded warrants to purchase 22,873,779 shares of common stock. The shares of common stock are being sold at an offering price of $1.45 per share, and the pre-funded warrants are being sold at an offering price of $1.449 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. In addition, Inhibikase has granted the underwriters a 30-day option to purchase up to an additional 10,344,827 shares of its common stock at the public offering price, less underwriting discounts and commissions. The aggregate gross proceeds to Inhibikase from this offering are expected to be approximately $100.0 million, before deducting underwriting discounts and commissions and other offering expenses, excluding the exercise of any pre-funded warrants. All of the securities being sold in the offering are being offered by Inhibikase. The offering is expected to close on November 24, 2025, subject to the satisfaction of customary closing conditions.
BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of pulmonary arterial hypertension (“PAH”), today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Inhibikase intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the total number of shares of common stock Inhibikase is offering, at the public offering price, less underwriting discounts and commissions. All of the securities being sold in the proposed offering are being offered by Inhibikase. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Phase 3 Study initiating in First Quarter of 2026 Single Pivotal Study Accelerates Potential FDA Approval Timeline by Approximately 3 Years BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension (“PAH”), today announced that it expects to advance IKT-001 to a global pivotal Phase 3 clinical study in PAH. The Phase 3 study, named IMPROVE-PAH ( I KT-001 for M easuring P ulmonary Vascular R esistance and O utcome V ariables in a Phase 3 E valuation of PAH ), is expected to be initiated in the first quarter of 2026.
BOSTON and ATLANTA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the quarter ended September 30, 2025 and highlighted recent developments. “During our third quarter of 2025, we continued to position the Company to advance IKT-001 toward a late-stage clinical trial in PAH,” said Mark Iwicki, Chief Executive Officer of Inhibikase.
BOSTON and ATLANTA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of pulmonary arterial hypertension (“PAH”), today announced the appointment of veteran biopharma executive Timothy Pigot as the Company's Chief Commercial and Strategy Officer. “Tim Pigot is an accomplished pharma industry business leader and a deeply respected expert in the PAH market landscape, and we are delighted to welcome him to the Inhibikase team,” said Mark Iwicki, Chief Executive Officer of Inhibikase.
BOSTON and ATLANTA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the quarter ended June 30, 2025 and highlighted recent developments.
Advancing IKT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension Advancing IKT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension
NEW YORK , May 5, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Inhibikase Therapeutics, Inc. (NASDAQ: IKT) on behalf of the company's shareholders. The investigation seeks to determine whether Inhibikase Therapeutics's directors breached their fiduciary duties in connection with recent corporate actions.
BOSTON and ATLANTA, April 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial hypertension (“PAH”), today announced the appointment of David McIntyre as Chief Financial Officer, effective April 14, 2025. “David has extensive experience in financial strategy and corporate governance, as well as an established reputation within the life sciences capital markets sector, and we are thrilled to welcome him as our new Chief Financial Officer,” said Mark Iwicki, Chief Executive Officer of Inhibikase Therapeutics.